BMY PE Ratio & Valuation,Is BMY Overvalued

BMY Relative Valuation

BMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMY is overvalued; if below, it's undervalued.

Historical Valuation

Bristol-Myers Squibb Co (BMY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.35 is considered Undervalued compared with the five-year average of 11.31. The fair price of Bristol-Myers Squibb Co (BMY) is between 63.36 to 83.02 according to relative valuation methord. Compared to the current price of 54.18 USD , Bristol-Myers Squibb Co is Undervalued By 14.48%.

Relative Value

Fair Zone

63.36-83.02

Current Price：54.18

14.48%

Undervalued

8.79

8.77

EV/EBITDA

Bristol-Myers Squibb Co. (BMY) has a current EV/EBITDA of 8.77. The 5-year average EV/EBITDA is 10.00. The thresholds are as follows: Strongly Undervalued below 1.53, Undervalued between 1.53 and 5.77, Fairly Valued between 14.24 and 5.77, Overvalued between 14.24 and 18.48, and Strongly Overvalued above 18.48. The current Forward EV/EBITDA of 8.77 falls within the Historic Trend Line -Fairly Valued range.

9.04

EV/EBIT

Bristol-Myers Squibb Co. (BMY) has a current EV/EBIT of 9.04. The 5-year average EV/EBIT is 10.01. The thresholds are as follows: Strongly Undervalued below 0.69, Undervalued between 0.69 and 5.35, Fairly Valued between 14.67 and 5.35, Overvalued between 14.67 and 19.33, and Strongly Overvalued above 19.33. The current Forward EV/EBIT of 9.04 falls within the Historic Trend Line -Fairly Valued range.

2.36

Bristol-Myers Squibb Co. (BMY) has a current PS of 2.36. The 5-year average PS is 2.75. The thresholds are as follows: Strongly Undervalued below 1.68, Undervalued between 1.68 and 2.21, Fairly Valued between 3.28 and 2.21, Overvalued between 3.28 and 3.81, and Strongly Overvalued above 3.81. The current Forward PS of 2.36 falls within the Historic Trend Line -Fairly Valued range.

9.75

P/OCF

Bristol-Myers Squibb Co. (BMY) has a current P/OCF of 9.75. The 5-year average P/OCF is 8.30. The thresholds are as follows: Strongly Undervalued below 6.36, Undervalued between 6.36 and 7.33, Fairly Valued between 9.28 and 7.33, Overvalued between 9.28 and 10.25, and Strongly Overvalued above 10.25. The current Forward P/OCF of 9.75 falls within the Overvalued range.

7.50

P/FCF

Bristol-Myers Squibb Co. (BMY) has a current P/FCF of 7.50. The 5-year average P/FCF is 7.83. The thresholds are as follows: Strongly Undervalued below 5.47, Undervalued between 5.47 and 6.65, Fairly Valued between 9.01 and 6.65, Overvalued between 9.01 and 10.19, and Strongly Overvalued above 10.19. The current Forward P/FCF of 7.50 falls within the Historic Trend Line -Fairly Valued range.

Bristol-Myers Squibb Co (BMY) has a current Price-to-Book (P/B) ratio of 5.75. Compared to its 3-year average P/B ratio of 5.11 , the current P/B ratio is approximately 12.47% higher. Relative to its 5-year average P/B ratio of 4.74, the current P/B ratio is about 21.26% higher. Bristol-Myers Squibb Co (BMY) has a Forward Free Cash Flow (FCF) yield of approximately 14.34%. Compared to its 3-year average FCF yield of 11.75%, the current FCF yield is approximately 22.11% lower. Relative to its 5-year average FCF yield of 10.76% , the current FCF yield is about 33.26% lower.

5.96

P/B

Median3y

5.11

Median5y

4.74

14.34

FCF Yield

Median3y

11.75

Median5y

10.76

Competitors Valuation Multiple

The average P/S ratio for BMY's competitors is 3.01, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 2.77%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of BMY decreased by 1.90% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 10.22 to 17.96.

The secondary factor is the Revenue Growth, contributed 2.77%to the performance.

Overall, the performance of BMY in the past 1 year is driven by Margin Expansion. Which is more sustainable.

2.77%

11.89B → 12.22B

Revenue Growth

75.73%

10.22 → 17.96

Margin Expansion

-80.40%

93.26 → 18.28

P/E Change

-1.90%

55.34 → 54.29

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Bristol-Myers Squibb Co (BMY) currently overvalued or undervalued?

What is Bristol-Myers Squibb Co (BMY) fair value?

BMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bristol-Myers Squibb Co (BMY) is between 63.36 to 83.02 according to relative valuation methord.

How does BMY's valuation metrics compare to the industry average?

The average P/S ratio for BMY's competitors is 3.01, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 2.77%, this premium appears unsustainable.

What is the current P/B ratio for Bristol-Myers Squibb Co (BMY) as of Dec 16 2025?

As of Dec 16 2025, Bristol-Myers Squibb Co (BMY) has a P/B ratio of 5.75. This indicates that the market values BMY at 5.75 times its book value.

What is the current FCF Yield for Bristol-Myers Squibb Co (BMY) as of Dec 16 2025?

As of Dec 16 2025, Bristol-Myers Squibb Co (BMY) has a FCF Yield of 14.34%. This means that for every dollar of Bristol-Myers Squibb Co’s market capitalization, the company generates 14.34 cents in free cash flow.

What is the current Forward P/E ratio for Bristol-Myers Squibb Co (BMY) as of Dec 16 2025?

As of Dec 16 2025, Bristol-Myers Squibb Co (BMY) has a Forward P/E ratio of 8.44. This means the market is willing to pay $8.44 for every dollar of Bristol-Myers Squibb Co’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bristol-Myers Squibb Co (BMY) as of Dec 16 2025?

As of Dec 16 2025, Bristol-Myers Squibb Co (BMY) has a Forward P/S ratio of 2.35. This means the market is valuing BMY at $2.35 for every dollar of expected revenue over the next 12 months.

BMY Valuation